Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). [electronic resource]
Producer: 20121220Description: 1523-30 p. digitalISSN:- 1536-4844
- Adalimumab
- Adult
- Aged
- Aged, 80 and over
- Anti-Inflammatory Agents -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Certolizumab Pegol
- Crohn Disease -- drug therapy
- Female
- Humans
- Immunoglobulin Fab Fragments -- administration & dosage
- Immunosuppressive Agents -- therapeutic use
- Infliximab
- Infusions, Intravenous
- Injections, Subcutaneous
- Male
- Middle Aged
- Patient Preference
- Polyethylene Glycols -- administration & dosage
- Prognosis
- Prospective Studies
- Surveys and Questionnaires
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
- Young Adult
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.